Literature DB >> 24123290

The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities.

Cihan Aydin1, Sourav Mukherjee, Alicia M Hanson, David N Frick, Celia A Schiffer.   

Abstract

Hepatitis C (HCV) protein 3/4A (NS3/4A) is a bifunctional enzyme comprising two separate domains with protease and helicase activities, which are essential for viral propagation. Both domains are stable and have enzymatic activity separately, and the relevance and implications of having protease and helicase together as a single protein remains to be explored. Altered in vitro activities of isolated domains compared with the full-length NS3/4A protein suggest the existence of interdomain communication. The molecular mechanism and extent of this communication was investigated by probing the domain-domain interface observed in HCV NS3/4A crystal structures. We found in molecular dynamics simulations that the two domains of NS3/4A are dynamically coupled through the interface. Interestingly, mutations designed to disrupt this interface did not hinder the catalytic activities of either domain. In contrast, substrate cleavage and DNA unwinding by these mutants were mostly enhanced compared with the wild-type protein. Disrupting the interface did not significantly alter RNA unwinding activity; however, the full-length protein was more efficient in RNA unwinding than the isolated protease domain, suggesting a more direct role in RNA processing independent of the interface. Our findings suggest that HCV NS3/4A adopts an "extended" catalytically active conformation, and interface formation acts as a switch to regulate activity. We propose a unifying model connecting HCV NS3/4A conformational states and protease and helicase function, where interface formation and the dynamic interplay between the two enzymatic domains of HCV NS3/4A potentially modulate the protease and helicase activities in vivo.
© 2013 The Protein Society.

Entities:  

Keywords:  HCV NS3/4A; bifunctional enzyme; catalytic activity; dynamic coupling; interdomain communication; protease-helicase interaction

Mesh:

Substances:

Year:  2013        PMID: 24123290      PMCID: PMC3843632          DOI: 10.1002/pro.2378

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  38 in total

1.  The Amber biomolecular simulation programs.

Authors:  David A Case; Thomas E Cheatham; Tom Darden; Holger Gohlke; Ray Luo; Kenneth M Merz; Alexey Onufriev; Carlos Simmerling; Bing Wang; Robert J Woods
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

2.  Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.

Authors:  Robert A Copeland
Journal:  Methods Biochem Anal       Date:  2005

3.  Crystal structure and activity of Kunjin virus NS3 helicase; protease and helicase domain assembly in the full length NS3 protein.

Authors:  Eloise Mastrangelo; Mario Milani; Michela Bollati; Barbara Selisko; Frederic Peyrane; Vittorio Pandini; Graziella Sorrentino; Bruno Canard; Peter V Konarev; Dmitri I Svergun; Xavier de Lamballerie; Bruno Coutard; Alexander A Khromykh; Martino Bolognesi
Journal:  J Mol Biol       Date:  2007-06-27       Impact factor: 5.469

Review 4.  Replication of hepatitis C virus.

Authors:  Darius Moradpour; François Penin; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2007-05-08       Impact factor: 60.633

5.  Rapid determination of enzyme kinetics from fluorescence: overcoming the inner filter effect.

Authors:  Mark O Palmier; Steven R Van Doren
Journal:  Anal Biochem       Date:  2007-07-18       Impact factor: 3.365

6.  Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients.

Authors:  Sophie Vallet; Stephanie Gouriou; Jean-Baptiste Nousbaum; Marie-Christine Legrand-Quillien; Alain Goudeau; Bertrand Picard
Journal:  J Med Virol       Date:  2005-04       Impact factor: 2.327

7.  Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus.

Authors:  Samuel G Mackintosh; Jeff Zhiqiang Lu; John B Jordan; Melody K Harrison; Bartek Sikora; Suresh D Sharma; Craig E Cameron; Kevin D Raney; Joshua Sakon
Journal:  J Biol Chem       Date:  2005-11-22       Impact factor: 5.157

Review 8.  Pathogenesis of hepatitis C-associated hepatocellular carcinoma.

Authors:  T Jake Liang; Theo Heller
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

9.  Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.

Authors:  Takuya Umehara; Kotaro Fukuda; Fumiko Nishikawa; Satoru Sekiya; Michinori Kohara; Tsunemi Hasegawa; Satoshi Nishikawa
Journal:  Nucleic Acids Symp Ser (Oxf)       Date:  2004

Review 10.  The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target.

Authors:  David N Frick
Journal:  Curr Issues Mol Biol       Date:  2007-01       Impact factor: 2.081

View more
  12 in total

Review 1.  Genetically modified proteins: functional improvement and chimeragenesis.

Authors:  Larissa Balabanova; Vasily Golotin; Anna Podvolotskaya; Valery Rasskazov
Journal:  Bioengineered       Date:  2015-07-25       Impact factor: 3.269

2.  A positively charged surface patch on the pestivirus NS3 protease module plays an important role in modulating NS3 helicase activity and virus production.

Authors:  Fengwei Zheng; Weicheng Yi; Weichi Liu; Hongchang Zhu; Peng Gong; Zishu Pan
Journal:  Arch Virol       Date:  2021-03-31       Impact factor: 2.574

3.  N-Naphthoyl-substituted indole thio-barbituric acid analogs inhibit the helicase activity of the hepatitis C virus NS3.

Authors:  John C Marecki; Suja Aarattuthodiyil; Alicia K Byrd; Narsimha R Penthala; Peter A Crooks; Kevin D Raney
Journal:  Bioorg Med Chem Lett       Date:  2018-12-13       Impact factor: 2.823

4.  Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.

Authors:  David R McGivern; Takahiro Masaki; William Lovell; Chris Hamlett; Susanne Saalau-Bethell; Brent Graham
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

5.  Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy.

Authors:  Jean Ndjomou; M Josie Corby; Noreena L Sweeney; Alicia M Hanson; Cihan Aydin; Akbar Ali; Celia A Schiffer; Kelin Li; Kevin J Frankowski; Frank J Schoenen; David N Frick
Journal:  ACS Chem Biol       Date:  2015-05-22       Impact factor: 5.100

6.  Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase.

Authors:  Noreena L Sweeney; Alicia M Hanson; Sourav Mukherjee; Jean Ndjomou; Brian J Geiss; J Jordan Steel; Kevin J Frankowski; Kelin Li; Frank J Schoenen; David N Frick
Journal:  ACS Infect Dis       Date:  2015-03-13       Impact factor: 5.084

7.  Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

Authors:  Stéphanie B N Serre; Sanne B Jensen; Lubna Ghanem; Daryl G Humes; Santseharay Ramirez; Yi-Ping Li; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

8.  Real-time fluorescence assays to monitor duplex unwinding and ATPase activities of helicases.

Authors:  Ali R Özeş; Kateryna Feoktistova; Brian C Avanzino; Enoch P Baldwin; Christopher S Fraser
Journal:  Nat Protoc       Date:  2014-06-19       Impact factor: 13.491

Review 9.  Unzippers, resolvers and sensors: a structural and functional biochemistry tale of RNA helicases.

Authors:  Ana Lúcia Leitão; Marina C Costa; Francisco J Enguita
Journal:  Int J Mol Sci       Date:  2015-01-22       Impact factor: 5.923

10.  Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.

Authors:  Debra A Ragland; Ellen A Nalivaika; Madhavi N L Nalam; Kristina L Prachanronarong; Hong Cao; Rajintha M Bandaranayake; Yufeng Cai; Nese Kurt-Yilmaz; Celia A Schiffer
Journal:  J Am Chem Soc       Date:  2014-08-18       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.